CSPC Innovation Pharmaceutical Co., Ltd. Stock price

Equities

300765

CNE100003K04

Food Processing

End-of-day quote Shenzhen S.E. 06:00:00 2024-02-29 pm EST 5-day change 1st Jan Change
34.08 CNY -0.44% Intraday chart for CSPC Innovation Pharmaceutical Co., Ltd. +11.01% -6.94%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * 2.71B 376M Sales 2024 * 3.23B 449M Capitalization 39.9B 5.54B
Net income 2023 * 792M 110M Net income 2024 * 886M 123M EV / Sales 2023 * 14.4 x
Net cash position 2023 * 1.02B 141M Net cash position 2024 * 1.45B 202M EV / Sales 2024 * 11.9 x
P/E ratio 2023 *
49.6 x
P/E ratio 2024 *
45.1 x
Employees 1,672
Yield 2023 *
0.44%
Yield 2024 *
0.44%
Free-Float 24.23%
More Fundamentals * Assessed data
Dynamic Chart
CSPC Baike's 2023 Profit Reaches 859 Million Yuan MT
CSPC Innovation Pharmaceutical Co., Ltd. announced a financing transaction CI
Tranche Update on CSPC Innovation Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
CSPC Innovation Pharmaceutical Co., Ltd.(SZSE:300765) added to Shenzhen Stock Exchange Component A Share Index CI
CSPC Innovation Pharmaceutical Co., Ltd.(SZSE:300765) added to Shenzhen Stock Exchange Component Index CI
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on CSPC Innovation Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
CSPC Innovation Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 421.8 million worth of its shares. CI
CSPC Innovation Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China’s NMPA Accepts CSPC Pharma’s License Application for Asthma Drug MT
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cspc Innovation Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on April 27, 2023 CI
CSPC Innovation Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022 CI
CSPC Innovation Pharmaceutical Co., Ltd. Approves Board Appointments CI
More news
1 day-0.44%
1 week+11.01%
Current month-0.44%
1 month+24.42%
3 months-22.63%
6 months+129.19%
Current year-6.94%
More quotes
1 week
31.01
Extreme 31.01
37.00
1 month
23.63
Extreme 23.63
37.00
Current year
23.63
Extreme 23.63
37.50
1 year
9.65
Extreme 9.65
48.74
3 years
6.43
Extreme 6.4333
48.74
5 years
5.97
Extreme 5.9748
48.74
10 years
5.97
Extreme 5.9748
48.74
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 15-12-31
Director of Finance/CFO 32 23-04-06
Members of the board TitleAgeSince
Chairman 55 -
Director/Board Member 61 15-12-31
Chairman - 15-12-31
More insiders
Date Price Change Volume
24-03-01 34.08 -0.44% 14,415,590
24-02-29 34.23 +5.03% 17,119,120
24-02-28 32.59 -4.93% 26,543,860
24-02-27 34.28 +6.86% 20,916,520
24-02-26 32.08 +4.50% 22,532,090

End-of-day quote Shenzhen S.E., March 29, 2024

More quotes
CSPC Innovation Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of functional foods. The Company's main products include caffeine products, vitamin products and other functional foods. The Company's caffeine products are mainly caffeine, including a small amount of theophylline, aminophylline and theobromine. The vitamin products are mainly vitamin C tablets, including a small amount of vitamin C drinks. The Company mainly distributes its products both in the domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.08 CNY
Average target price
49.45 CNY
Spread / Average Target
+45.10%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock CSPC Innovation Pharmaceutical Co., Ltd. - Shenzhen S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW